Epidemiological study of second-line treated non-small cell lung cancer (NSCLC) with HER2 mutation in Japan

Epidemiological study of second-line treated non-small cell lung cancer (NSCLC) with HER2 mutation in Japan - Epidemiological study of second-line treated non-small cell lung cancer (NSCLC) with HER2 mutation in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055395

Enrollment

2700

Registered

2024-09-02

Start date

2024-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer (NSCLC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and older at registration in the C-CAT database 2. Patients who have NSCLC diagnostic information 3. Patients with a medical record of second-line lung cancer treatment information in the C-CAT database

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
Patient information at registration to C-CAT database 1. Patient characteristics 2. Clinical characteristics 3. Genetic alterations	—

Secondary

Measure	Time frame
1. Second-line lung cancer treatment types 2. Overall response rate (ORR) 3. Disease control rate (DCR) 4. Time on treatment (ToT) 5. Overall survival (OS) 6. Reasons for the second-line lung cancer treatment termination	—

Countries

Japan

Contacts

Public ContactHana Kimura

Nippon Boehringer Ingelheim Co., Ltd Medicine Division Real World Evidence Japan

hana.kimura@boehringer-ingelheim.com070-2674-6485

Outcome results